Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction
Links shared publicly online about this topic.
- 684total visits
Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction
View full resource at medicalnewstoday.com
Tags: Cancer, Prostate Cancer, Prostate, Benign Prostatic Hypertrophy Medication, Pharma, Men's Health, FDA, Avodart
Most Recently Shared on December 2, 2010 at 6:05 pm By:
Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction http://mnt.to/3Nsc #regulatory
Also Shared By:
FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction
news-medical.net — “GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).” View full resource at news-medical.net
Most Recently Shared on December 2, 2010 at 9:06 am By:
Prostate Cancer: FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction: GlaxoSmit... http://bit.ly/e7cd6v
Advertisement
medical_tweets
@medical_tweets
Avodart Reviewed By FDA Advisory Committee For Prostate Cancer Risk Reduction GlaxoSmithKline (NYSE: GSK) announced the.. http://dld.bz/8Wrf
1 year ago...